Pentavalent outer membrane vesicles of Vibrio cholerae induce adaptive immune response and protective efficacy in both adult and passive suckling mice models

Microbes and Infection

Volumn 17, Issue 3, 2015, Pages 215-227

  Sinha, Ritam ^a   Koley, Hemanta ^a   Nag, Dhrubajyoti ^a   Mitra, Soma ^a   Mukhopadhyay, Asish K ^a   Chattopadhyay, Brajadulal ^b  

^a NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^b JADAVPUR UNIVERSITY   (India)

Author keywords

Adaptive immunity and passive protection; Cholera; Cholera pentavalent OMVs (CPMVs); Outer membrane vesicles (OMVs); Vibrio cholerae

Indexed keywords

BACTERIAL ANTIGEN; CD4 ANTIGEN; CHOLERA PENTAVALENT OUTER MEMBRANE VESICLE ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; UNCLASSIFIED DRUG; CHOLERA VACCINE; VACCINE;

ADAPTIVE IMMUNITY; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; MALE; MOUSE; MUCOSAL IMMUNITY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SUCKLING ANIMAL; TH17 CELL; TH2 CELL; VIBRIO CHOLERAE; ANIMAL; ANIMAL MODEL; IMMUNOLOGY; PHYSIOLOGY;

MUS; VIBRIO CHOLERAE;

ADAPTIVE IMMUNITY; ANIMALS; ANIMALS, NEWBORN; CHOLERA VACCINES; FEMALE; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-13; INTERLEUKIN-17; INTERLEUKIN-4; INTERLEUKIN-6; MICE; MODELS, ANIMAL; VACCINES, COMBINED; VIBRIO CHOLERAE;

EID: 84923521206     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2014.10.011     Document Type: Article

References (56)

1. Siddique A.K., Nair G.B., Alam M., Sack D.A., Huq A., Nizam A., et al. El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect 2010, 138:347-352.
2. World Health Organization Cholera. Wkly Epidemiol Rec 2010, 31:325-338.
3. Blokesch M., Schoolnik G.K. Serogroup conversion of Vibrio choleraein aquatic reservoirs. PLoS Pathog 2007, 3:e81.
4. Larocque R.C., Harris J.B., Dziejman M., Li X., Khan A.I., Faruque A.S., et al. Transcriptional profiling of Vibrio cholerae recovered directly from patient specimens during early and late stages of human infection. Infect Immun 2005, 73:4488-4493.
5. Garg P., Nandy R.K., Chaudhury P., Chowdhury N.R., De K., Ramamurthy T., et al. Emergence of Vibrio cholerae O1 biotype El Tor serotype Inaba from the prevailing O1 Ogawa serotype strains in India. J Clin Microbiol 2000, 38(11):4249-4253.
6. Pal B.B., Khuntia H.K., Samal S.K., Kerketta A.S., Kar S.K., Karmakar M., et al. Large outbreak of cholera caused by El Tor variant Vibrio cholerae O1 in the eastern coast of Odisha, India during 2009. Epidemiol Infect 2013, 141(12):2560-2567.
7. Nair G.B., Faruque S.M., Bhuiyan N.A., Kamruzzaman M., Siddique A.K., Sack D.A. New variants of Vibrio cholerae O1 biotype El Tor with attributes of the classical biotype from hospitalized patients with acute diarrhea in Bangladesh. J Clin Microbiol 2002, 40:3296-3299.
8. Alam M., Hasan N.A., Sadique A., Bhuiyan N.A., Ahmed K.U., Nusrin S., et al. Seasonal cholera caused by Vibriocholerae serogroups O1 and O139 in the coastal aquatic environment of Bangladesh. Appl Environ Microbiol 2006, 72(6):4096-4104.
9. Yu L., Zhou Y., Wang R., Lou J., Zhang L., Li J., et al. Multiple antibiotic resistance of Vibrio cholerae serogroup O139 in China from 1993 to 2009. PLoS One 2012, 7(6):e38633.
10. Dutta D., Chowdhury G., Pazhani G.P., Guin S., Dutta S., Ghosh S., et al. Vibrio cholerae non-O1, non-O139 serogroups and cholera-like diarrhea, Kolkata, India. Emerg Infect Dis 2013, 19:464-467.
11. Luo Y., Ye J., Jin D., Ding G., Zhang Z., Mei L., et al. Molecular analysis of non-O1/non-O139 Vibrio cholerae isolated from hospitalized patientsin China. BMC Microbiol 2013, 13:52.
12. Albert M.J., Alam K., Rahman A.S., Huda S., Sack R.B. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal. J Infect Dis 1994, 169(3):709-710.
13. Qadri F., Wennerås C., Albert M.J., Hossain J., Mannoor K., Begum Y.A., et al. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect Immun 1997, 65(9):3571-3576.
14. Andrews J.R., Basu S. Transmission dynamics and control of cholera in Haiti: an epidemic model. Lancet 2011, 377(9773):1248-1255.
15. Mukandavire Z., Liao S., Wang J., Gaff H., Smith D.L., Morris J.G. Estimating the reproductive numbers for the 2008-2009 cholera outbreaks in Zimbabwe. Proc Natl Acad Sci U S A 2011, 108(21):8767-8772.
16. Kabir S. Critical analysis of compositions and protective efficacies of oral killed cholera vaccines. Clin Vaccine Immunol 2014, 21(9):1195-1205.
17. Sur D., Lopez A.L., Kanungo S., Paisley A., Manna B., Ali M., et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2009, 374(9702):1694-1702.
18. Kuehn M.J., Kesty N.C. Bacterial outer membrane vesicles and the host-pathogen interaction. Genes Dev 2005, 19:2645-2655.
19. Mitra S., Chakrabarti M.K., Koley H. Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis. Vaccine 2013, 31(31):3163-3173.
20. Alaniz R.C., Deatherage B.L., Lara J.C., Cookson B.T. Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity invivo. J Immunol 2007, 179:7692-7701.
21. Kim O.Y., Hong B.S., Park K.S., Yoon Y.J., Choi S.J., Lee W.H., et al. Immunization with Escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses. J Immunol 2013 Apr 15, 190(8):4092-4102.
22. Haneberg B., Dalseg R., Wedege E., Høiby E.A., Haugen I.L., Oftung F., et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun 1998, 66:1334-1341.
23. Roy N., Barman S., Ghosh A., Pal A., Chakraborty K., Das S.S., et al. Immunogenicity and protective efficacy of Vibrio cholerae outer membrane vesicles in rabbit model. FEMS Immunol Med Microbiol 2010, 60:18-27.
24. Schild S., Nelson E.J., Bishop A.L., Camilli A. Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect Immun 2009, 77(1):472-484.
25. Bishop A.L., Schild S., Patimalla B., Klein B., Camilli A. Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by anti-lipopolysaccharide antibodies that inhibit bacterial motility. Infect Immun 2010, 78:4402-4420.
26. Bishop A.L., Tarique A.A., Patimalla B., Calderwood S.B., Qadri F., Camilli A. Immunization of mice with Vibrio cholerae outer-membrane vesicles protects against hyperinfectious challenge and blocks transmission. J Infect Dis 2012, 205(3):412-421.
27. Leitner D.R., Feichter S., Schild-Prüfert K., Rechberger G.N., Reidl J., Schild S. Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen. Infect Immun 2013, 81:2379-2393.
28. Balsalobre C., Silván J.M., Berglund S., Mizunoe Y., Uhlin B.E., Wai S.N. Release of the type I secreted alpha-haemolysin via outer membrane vesicles from Escherichia coli. Mol Microbiol 2006, 59:99-112.
29. Elson C.O., Ealding W., Lefkowitz J. A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions. J Immunol Methods 1984, 24(67):101-108.
30. Keren D.F. Enzyme-linked immunosorbent assay for immunoglobulin G and immunoglobulin A antibodies to Shigella flexneri antigens. Infect Immun 1979, 24:441-448.
31. Lutz M.B., Kukutsch N., Ogilvie A.L., Rössner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223:77-92.
32. Chatterjee D., ChaudhuriK Vibrio cholerae O395 outer membrane vesicles modulate intestinal epithelial cells in a NOD1 protein-dependent manner and induce dendritic cell-mediated Th2/Th17 cell responses. J Biol Chem 2013, 288:4299-4309.
33. Tokuhara D., Yuki Y., Nochi T., Kodama T., Mejima M., Kurokawa S., et al. Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine. Proc Natl Acad Sci U S A 2010, 11(107):8794-8799.
34. Kuchta A., Rahman T., Sennott E.L., Bhuyian T.R., Uddin T., Rashu R., et al. Vibrio cholerae O1 infection induces proinflammatory CD4+ T-cell responses in blood and intestinal mucosa of infected humans. Clin Vaccine Immunol 2011, 18(8):1371-1377.
35. Kabir S. Antigenic analysis of Vibrio cholerae O1 by crossed immune electrophoresis. Zent bl Bakteriol Mikrobiol Hyg A 1989, 270(3):361-372.
36. diTommaso A., de Magistris M.T., Bugnoli M., Marsili I., Rappuoli R., Abrignani S. Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing. Infect Immun 1994, 62(5):1830-1834.
37. Collins B.S. Gram-negative outer membrane vesicles in vaccine development. Discov Med 2011, 12:7-15.
38. Anh D.D., Canh do G., Lopez A.L., Thiem V.D., Long P.T., Son N.H., et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 2007, 25(6):1149.
39. Paulovicová E., Machová E., Hostacká A., Bystrický S. Immunological properties of complex conjugates based on Vibrio cholerae O1 Ogawa lipopolysaccharide antigen. Clin Exp Immunol 2006, 144(3):521-527.
40. Gupta R.K., Taylor D.N., Bryla D.A., Robbins J.B., Szu S.C. Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers. Infect Immun 1998, 66(7):3095-3099.
41. Sakharwade S.C., Sharma P.K., Mukhopadhaya A. Vibrio cholerae porin OmpU induces pro-inflammatory responses, but down-regulates LPS-mediated effects in RAW 264.7, THP-1 and human PBMCs. PLoS One 2013, 27(8):e76583.
42. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
43. Staats H.F., Ennis F.A. IL-1 is an effective adjuvant formucosal and systemic immune responses when co-administered with protein immunogens. J Immunol 1999, 162:6141-6147.
44. Beagley K.W., Eldridge J.H., Lee F., Kiyono H., Everson M.P., Koopman W.J., et al. Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med 1989, 2133-2148.
45. Yamamoto M., Vancott J.L., Okahashi N., Marinaro M., Kiyono H., Fujihashi K., et al. The role of Th1 and Th2 cells for mucosal IgA responses. Ann N Y Acad Sci 1996, 13(778):64-71.
46. Vajdy M., Kosco-Vilbois M.H., Kopf M., Köhler G., Lycke N. Impaired mucosal immune responses in interleukin 4-targeted mice. J Exp Med 1995, 1(181):41-53.
47. Beagley K.W., Eldridge J.H., Kiyono H., Everson M.P., Koopman W.J., Honjo T., et al. Recombinant murine IL-5 induces high rate IgA synthesis in cycling IgA-positive Peyer's patch B cells. J Immunol 1988, 141:2035-2042.
48. Curtis M.M., Way S.S. Interleukin-17 in host defence against bacterial,mycobacterial and fungal pathogens. Immunology 2009, 126:177-185.
49. Deen J.L., von Seidlein L., Sur D., Agtini M., Lucas M.E., Lopez A.L., et al. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis 2008, 2(2):173.
50. Mahalanabis D., Lopez A.L., Sur D., Deen J., Manna B., Kanungo S., et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell,oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One 2008, 3(6):2323.
51. Pal S.C., Deb B.C., Sen Gupta P.G., De S.P., Sircar B.K., Sen D., et al. A controlled field trial of an aluminum phosphate-adsorbed cholera vaccine in Calcutta. Bull World Health Organ 1980, 58(5):741-745.
52. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(Suppl. 2):B3-B12.
53. de Kleijn E.D., de Groot R., Labadie J., Lafeber A.B., van den Dobbelsteen G., van Alphen L., et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 2000, 18(15):1456-1466.
54. Winner L., Mack J., Weltzin R., Mekalanos J.J., Kraehenbuhl J.P., Neutra M.R. New model for analysis of mucosal immunity: intestinal secretion of specific monoclonal immunoglobulin A from hybridoma tumors protects against Vibrio cholerae infection. Infect Immun 1991, 59:977-982.
55. Clemens J.D., Sack D.A., Harris J.R., Khan M.R., Chakraborty J., Chowdhury S., et al. Breast feeding and the risk of severe cholera in rural Bangladeshi children. Am J Epidemiol 1990, 131(3):400-411.
56. van de Waterbeemd B., Zomer G., Kaaijk P., Ruiterkamp N., Wijffels R.H., van den Dobbelsteen G.P., et al. Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis. PLoS One 2013, 8(5):e65157.